{
    "ticker": "PRCH",
    "name": "Precipio, Inc.",
    "description": "Precipio, Inc. is a biotechnology company specializing in the development and commercialization of innovative diagnostic solutions for healthcare providers. Founded in 2015, Precipio focuses on transforming the diagnostic landscape through cutting-edge technologies that enhance the accuracy and speed of patient testing. The company's flagship product, the HemeScreen, is a comprehensive diagnostic tool designed for hematological cancers, providing healthcare professionals with critical insights to guide treatment decisions. Precipio's mission is to improve patient outcomes by delivering timely and precise diagnostic information, thereby enabling personalized medicine. The company also offers a suite of services that include next-generation sequencing and molecular diagnostics, contributing to a holistic approach to cancer diagnostics. By leveraging advanced technologies and fostering strategic partnerships, Precipio aims to expand its product offerings and reach within the oncology space. Committed to innovation and excellence, Precipio is dedicated to addressing the unmet needs in cancer diagnostics, ultimately striving to enhance the quality of care for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Newark, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.precipiodx.com",
    "ceo": "Ilan Danieli",
    "social_media": {
        "twitter": "https://twitter.com/PrecipioDx",
        "linkedin": "https://www.linkedin.com/company/precipio-inc/"
    },
    "investor_relations": "https://ir.precipiodx.com",
    "key_executives": [
        {
            "name": "Ilan Danieli",
            "position": "CEO"
        },
        {
            "name": "Mark A. C. Hellerstein",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Solutions",
            "products": [
                "HemeScreen",
                "Next-Generation Sequencing"
            ]
        },
        {
            "category": "Molecular Diagnostics",
            "products": [
                "Custom Diagnostic Panels"
            ]
        }
    ],
    "seo": {
        "meta_title": "Precipio, Inc. | Innovative Diagnostic Solutions for Healthcare",
        "meta_description": "Discover Precipio, Inc., a biotechnology company revolutionizing cancer diagnostics with innovative solutions like HemeScreen and next-generation sequencing.",
        "keywords": [
            "Precipio",
            "Biotechnology",
            "Cancer Diagnostics",
            "HemeScreen",
            "Healthcare",
            "Molecular Diagnostics"
        ]
    },
    "faq": [
        {
            "question": "What does Precipio specialize in?",
            "answer": "Precipio specializes in the development and commercialization of diagnostic solutions for healthcare providers, with a focus on hematological cancers."
        },
        {
            "question": "Who is the CEO of Precipio?",
            "answer": "Ilan Danieli is the CEO of Precipio, Inc."
        },
        {
            "question": "Where is Precipio headquartered?",
            "answer": "Precipio is headquartered in Newark, New Jersey, USA."
        },
        {
            "question": "What are Precipio's main products?",
            "answer": "Precipio's main products include the HemeScreen and various next-generation sequencing services."
        },
        {
            "question": "When was Precipio founded?",
            "answer": "Precipio was founded in 2015."
        }
    ],
    "competitors": [
        "EXAS",
        "NTRA",
        "PACB",
        "NVTA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}